Stivarga

(Regorafenib)

ApprovedSmall molecule

Regorafenib is used to treat certain advanced cancers, including colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma. It works by blocking proteins that help cancer cells grow and spread.[2] Stivarga is currently approved and in use across 50 indications[4].[1]

Stivarga is one of 906 small molecule programs targeting Fatigue. It is currently in Approved.

Indications

268

Total Trials

Active Trials

905

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

Colorectal CarcinomaApproved

MetastasisActive, not recruiting

Colon AdenocarcinomaApproved

Liver NeoplasmActive, not recruiting

Esophageal CancerActive, not recruiting

OsteosarcomaActive, not recruiting

Macular DegenerationActive, not recruiting

Adenoid Cystic CarcinomaActive, not recruiting

Intestinal CancerActive, not recruiting

Ovarian CarcinomaActive, not recruiting

Colorectal CarcinomaApproved

Approved

MetastasisPhase 2

Active, not recruiting

Colon AdenocarcinomaApproved

Approved

Liver NeoplasmPreclinical

Active, not recruiting

Esophageal CancerPhase 3

Active, not recruiting

OsteosarcomaPhase 2

Active, not recruiting

Macular DegenerationPhase 2

Active, not recruiting

Adenoid Cystic CarcinomaPhase 2

Active, not recruiting

Intestinal CancerPhase 1/Phase 2

Active, not recruiting

Ovarian CarcinomaPhase 2

Active, not recruiting

Showing 10 of 49 indications

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Stivarga

Bayer

Approved

1 2

Activella

Eli Lilly

Preclinical

—3

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 4

Nitrostat

VViatris Specialty LLC

Preclinical

1 5

Proventil

Mylan Pharmaceuticals Inc

Preclinical

1 6

Rayaldee

OOrganon and Co

Preclinical

1 7

Achromycin V

WWyeth-Lederle Vaccines

Preclinical

—8

Biological Data

UUniversity Hospital, Bordeaux

Preclinical

3 9

Netakimab

SSPH-BIOCAD (HK) Limited

Preclinical

1 10

Saliva Collection

DDirection Centrale du Service de Santé des Armées

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Metastatic Colorectal Cancer

NCT03844620

Phase 3Active, not recruiting

Metastatic Colorectal Cancer

NCT03829462

Phase 2Recruiting

Colorectal Cancer

NCT05057052

Q4 2026

Phase 1Active, not recruiting

Hepatocellular Carcinoma

NCT05644379

Phase 1/2Active, not recruiting

Biliary Tract Cancer

NCT04781192

Phase 2Recruiting

Metastatic Colorectal Cancer

NCT05985109

Clinical

Trials by Indication[1]

Metastatic Colorectal Cancer47 trials

Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite Stable Metastatic Colorectal Cancer

Completed·HHunan Cancer Hospital··NCT05942768·103 enrolled

Regorafenib and PD-1 Antibody in Combination With Radiotherapy for pMMR/MSS Metastatic Colorectal Cancer

Unknown status·SSun Yat-sen University·Phase 2·NCT04030260·28 enrolled

Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer

Withdrawn·CCytoDyn, Inc.·Phase 2·NCT05730673

Show 44 more trials

Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancer

Terminated·UUNICANCER·Phase 2·NCT04450836·234 enrolled

Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers

Recruiting·—·Phase 2·NCT06425133·174 enrolled

Regorafenib and XELOX as 2nd Line Treatment in Metastatic Colorectal Cancer

Unknown status·—·Phase 1/2·NCT04008511·54 enrolled

Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer

Active, not recruiting·—·Phase 2·NCT04117945·22 enrolled

Regorafenib Alone or in Combination With Hypofractionated/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer

Recruiting·FFudan University·Phase 2·NCT05963490·108 enrolled

Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab

Terminated·SSpanish Cooperative Group for the Treatment of Digestive Tumours (TTD)·Phase 2·NCT02175654·15 enrolled

Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT04776148·563 enrolled

Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT03844620·100 enrolled

Metastatic Colorectal Cancer Treated With Regorafenib and FOLFIRI

Completed·KKaohsiung Medical University Chung-Ho Memorial Hospital·N/A·NCT03698253·41 enrolled

Regorafenib in Metastatic Colorectal Cancer

Completed·UUniversity of Rochester·Phase 2·NCT02466009·27 enrolled

Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers

Unknown status·GGerald Batist·Phase 2·NCT01949194·48 enrolled

A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer

Completed·EEpicentRx, Inc.·Phase 2·NCT02096354·62 enrolled

Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer

Active, not recruiting·UUniversity of Southern California·Phase 1/2·NCT03657641·75 enrolled

Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated in Patients With Previously Treated Metastatic Colorectal Cancer

Unknown status·KKaohsiung Medical University Chung-Ho Memorial Hospital·Phase 2·NCT03880877·153 enrolled

Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients

Active, not recruiting·IInstitut du Cancer de Montpellier - Val d'Aurelle·Phase 3·NCT03829462·377 enrolled

Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer

Active, not recruiting·EExelixis·Phase 3·NCT05425940·901 enrolled

An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.

Completed· Arcus Biosciences logo

Arcus Biosciences·Phase 1/2·NCT04660812·227 enrolled

Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer

Completed·—·Phase 2·NCT02368886·123 enrolled

Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy

No longer available· Bayer logo

Bayer··NCT01538680

A Study of JMT101 in Patients With Metastatic Colorectal Cancer

Unknown status·SShanghai JMT-Bio Inc.·Phase 2·NCT06089330·102 enrolled

Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC).

Completed· Bayer logo

Bayer·Phase 4·NCT03564938·100 enrolled

Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Colorectal Cancer With Mutations In RAS Genes

Recruiting·SSergey Orlov, MD·Phase 2·NCT06949982·60 enrolled

Assessment of Physical Activity During Therapy With Regorafenib for Metastatic Colorectal Cancer

Completed· Bayer logo

Bayer··NCT02347852·25 enrolled

5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer

Recruiting·TThe Methodist Hospital Research Institute·Phase 2·NCT06887218·57 enrolled

Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT01298570·181 enrolled

Metastatic Colorectal Cancer Patients With Long-term Response to Regorafenib

Completed· Bayer logo

Bayer··NCT03386825·76 enrolled

First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib

Completed· Bayer logo

Bayer·Phase 2·NCT01289821·54 enrolled

Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy

Completed· Bayer logo

Bayer·Phase 3·NCT01103323·760 enrolled

A Phase 4 Study of Regorafenib in Metastatic Colorectal Cancer - Does Educating Physicians Change Patient Outcomes?

Terminated· Bayer logo

Bayer·Phase 4·NCT02287025·23 enrolled

A Real-World Study to Learn More About the Order of Different Treatments and Their Effects in People With Metastatic Colorectal Cancer Receiving Their Third and Fourth Line of Treatment

Completed· Bayer logo

Bayer··NCT06137170·121 enrolled

Investigating the Use of Regorafenib (Stivarga®) in Patients With Metastatic Colorectal Cancer (mCRC) After Failure of Standard Therapy

Completed· Bayer logo

Bayer··NCT01959269·483 enrolled

An Observational Study to Learn More About the Long-Term Responses to Treatment With Regorafenib in Patients With Metastatic Colorectal Cancer in the United States

Completed· Bayer logo

Bayer··NCT06029010·2,326 enrolled

Asian Subjects With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy

Completed· Bayer logo

Bayer·Phase 3·NCT01584830·204 enrolled

An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions

Completed· Bayer logo

Bayer··NCT05839951·818 enrolled

Regorafenib in Subjects With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard Therapy

Completed· Bayer logo

Bayer·Phase 3·NCT01853319·100 enrolled

Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer

Completed·—·Phase 2·NCT04534218·49 enrolled

Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT02195011·26 enrolled

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)

Terminated· Roche logo

Roche·Phase 1/2·NCT03555149·96 enrolled

A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer

Terminated·GGeorgetown University·Phase 2·NCT02402036·10 enrolled

A Trial of Regorafenib Plus Lorigerlimab as Neoadjuvant Therapy for Patients With pMMR/MSS, Resectable, Lung-limited Metastatic Colorectal Cancer

Withdrawn·MM.D. Anderson Cancer Center·Phase 1/2·NCT07137390

Regorafenib in Combination With TAS-102 in Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard Therapy

Completed·AAIO-Studien-gGmbH·Phase 1·NCT03305913·12 enrolled

KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer

Recruiting·PPeking University Cancer Hospital & Institute·Phase 2·NCT05985109·98 enrolled

Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab

Completed·LLudwig-Maximilians - University of Munich·Phase 3·NCT02934529·673 enrolled

Regorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal Cancer

Completed·SSpanish Cooperative Group for the Treatment of Digestive Tumours (TTD)·Phase 2·NCT01875380·46 enrolled

Colorectal Cancer29 trials

Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME)

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT05900648

Regorafenib Plus PD-1 Inhibitor in Patients With Colorectal Cancer

Unknown status·SShanghai Changzheng Hospital·Phase 1/2·NCT04110093·120 enrolled

Regorafenib + Panitumumab for Colorectal Cancers

Terminated·UUniversity of Utah·Phase 1·NCT02199223·2 enrolled

Show 26 more trials

Regorafenib Assessment in Refractory Advanced Colorectal Cancer(RegARd-C)

Completed·JJules Bordet Institute·Phase 2·NCT01929616·141 enrolled

A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer

Not yet recruiting·—·Phase 1·NCT06283134·60 enrolled

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT05600309·94 enrolled

Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver Metastasis

Recruiting·FFudan University·Phase 2·NCT05057052·25 enrolled

Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX

Terminated·UUS Oncology Research·Phase 2·NCT02425683·24 enrolled

Real World Study of Regorafenib Versus Fruquintinib in Colorectal Cancer

Unknown status·PPeking University··NCT04431791·268 enrolled

Study of Ruxolitinib in Colorectal Cancer Patients

Terminated· Incyte logo

Incyte·Phase 2·NCT02119676·396 enrolled

A Clinical Study of T3011 in Combination With Regorafenib in Patients With Advanced Colorectal Cancer

Unknown status·WWest China Hospital·Phase 1·NCT06200363·15 enrolled

Clinical Evaluation - A Phase IIA Proof of Concept Study of Regorafenib (Bayer 73-4506) in Biopsy-amenable Asian Colorectal Cancer Patients

Unknown status·NNational University Hospital, Singapore·Phase 2/3·NCT01189903

A Clincal Study of Max-40279-01 in Patients With Advanced Colorectal Cancer

Unknown status·MMaxinovel Pty., Ltd.·Phase 2·NCT05130021·130 enrolled

Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients

Unknown status·—·Phase 1/2·NCT05426811·50 enrolled

Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]

Suspended·MM.D. Anderson Cancer Center·Phase 2·NCT07071961·16 enrolled

Regorafenib in Subjects With Antiangiogenic-naive and Chemotherapy-refractory Advanced Colorectal Cancer

Completed· Bayer logo

Bayer·Phase 2·NCT02465502·59 enrolled

JS001 Combined With Regorafenib in Patients With Advanced Colorectal Cancer

Unknown status·SSun Yat-sen University·Phase 1/2·NCT03946917·44 enrolled

Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)

Completed· Bayer logo

Bayer·Phase 2·NCT04126733·70 enrolled

STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer

Recruiting·NNational Cancer Institute, Naples·Phase 2·NCT07213570·60 enrolled

Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial

Unknown status·OOspedale Policlinico San Martino·Phase 2·NCT05382741·182 enrolled

Colorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo-Controlled Phase-III STudy

Terminated· Bayer logo

Bayer·Phase 3·NCT01939223·25 enrolled

"Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer"

Recruiting·—·Phase 2·NCT06829355·52 enrolled

Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer

Withdrawn·—·Phase 2·NCT06575725

Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT03712943·52 enrolled

Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer

Terminated·AAnwaar Saeed·Phase 2·NCT06006923·1 enrolled

Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer

Active, not recruiting·—·Phase 2·NCT03992456·12 enrolled

Safety Study of Regorafenib With PF-03446962 to Treat Colorectal Cancer

Completed·—·Phase 1·NCT02116894·11 enrolled

Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer

Completed·TThe University of Texas Health Science Center at San Antonio·Phase 2·NCT02316340·42 enrolled

QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine

Terminated·IImmunityBio, Inc.·Phase 1/2·NCT03563157·2 enrolled

Hepatocellular Carcinoma17 trials

Combination of Regorafenib and Nivolumab in Unresectable Hepatocellular Carcinoma

Completed·—·Phase 2·NCT04310709·42 enrolled

A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)

Terminated·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT04985136·1 enrolled

Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma

Recruiting·ZZe-yang Ding, MD··NCT05713994·300 enrolled

Show 14 more trials

Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma

Recruiting·UUniversity of Miami·Phase 2·NCT06902246·30 enrolled

Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma

Recruiting·TTongji Hospital··NCT05717738·300 enrolled

Regorafenib Alone or in Combined With Transcatheter Arterial ChEmoembolization in Treatment of Advanced Hepatocellular Carcinoma After First Line Targeted Therapy

Unknown status·WWenBo Guo··NCT05811481·192 enrolled

Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma

Recruiting·ZZhejiang Hisun Pharmaceutical Co. Ltd.·Phase 2·NCT07310173·75 enrolled

A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma

Not yet recruiting·FFudan University·Phase 2·NCT07328009·350 enrolled

Use of Sorafenib and/or Regorafenib in Liver Cancer (Hepatocellular Carcinoma) Subsequent to Another Systemic First-line Treatment

Terminated· Bayer logo

Bayer··NCT03644511·3 enrolled

Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)

Completed· Bayer logo

Bayer··NCT03289273·1,010 enrolled

Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma

Completed· Bayer logo

Bayer·Phase 3·NCT01774344·573 enrolled

Dose-escalation of Regorafenib in Advanced Hepatocellular Carcinoma

Unknown status·IInstituto do Cancer do Estado de São Paulo·Phase 2·NCT05622136·28 enrolled

A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma

Recruiting·ZZhejiang University·Phase 1·NCT05155189·72 enrolled

Tauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab

Recruiting·FFudan University·Phase 2·NCT07100392·141 enrolled

Comparing the Combination of Trastuzumab and Regorafenib With Regorafenib Monotherapy for Advanced Hepatocellular Carcinoma After First-line Treatment

Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07078305·134 enrolled

A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Advanced Hepatocellular Carcinoma

Active, not recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 1·NCT05644379·30 enrolled

A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma

Not yet recruiting·NNanjing Sanhome Pharmaceutical, Co., Ltd.·Phase 2/3·NCT07392866·120 enrolled

Gastrointestinal Stromal Tumor7 trials

A Study of Regorafenib Combined With Envafolimab for Metastatic Gastrointestinal Stromal Tumors With Kit Gene Exon 17 Mutation That Failed Standard Treatment

Not yet recruiting·PPeking University·Phase 2·NCT06772233·100 enrolled

A Multicenter, Open-label Clinical Study to Evaluate the Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

Not yet recruiting·NNingbo Newbay Technology Development Co., Ltd·Phase 2/3·NCT07379047·255 enrolled

An Observational Study to Learn More About Treatment With Regorafenib in People With Advanced Gastrointestinal Stromal Tumors in the United States

Completed· Bayer logo

Bayer··NCT06321055·136 enrolled

Show 4 more trials

Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor

Completed·—·Phase 2·NCT01068769·34 enrolled

Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy (Managed Access Program)

No longer available· Bayer logo

Bayer··NCT01689376

Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy

No longer available· Bayer logo

Bayer··NCT01646593

Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST)

Completed· Bayer logo

Bayer·Phase 3·NCT01271712·199 enrolled

Treatment7 trials

Carelizumab Combined With Regorafenib in the Treatment of HCC（CARE-2020）

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2·NCT04806243·69 enrolled

[18F]FLT-PET as a Predictive Imaging Biomaker of Treatment Responses to Regorafenib

Completed·—·N/A·NCT02175095·68 enrolled

A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Treatment of Biliary Systemic Tumours

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 1·NCT05644392·30 enrolled

Show 4 more trials

Cadonilimab Combined With Regorafenib as A Third-line Treatment in Patients With MSS CRLM

Recruiting·JJin-hong Chen·Phase 2·NCT06455254·44 enrolled

HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure

Unknown status·TThe Central Hospital of Lishui City·N/A·NCT05233358·176 enrolled

An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib

Active, not recruiting· Incyte logo

Incyte·Phase 2·NCT02955940·10 enrolled

Study Comparing Different Dose Approaches of Induction Treatment of Regorafenib in MCRC

Completed·SSpanish Cooperative Group for the Treatment of Digestive Tumours (TTD)·Phase 2·NCT02835924·299 enrolled

64 more indications

Tics6 trials

Effect of Rifampin on the Pharmacokinetics of BAY73-4506

Completed· Bayer logo

Bayer·Phase 1·NCT01322438·24 enrolled

Effect of Ketoconazole on Regorafenib (BAY73-4506) Pharmacokinetics

Completed· Bayer logo

Bayer·Phase 1·NCT01318265·24 enrolled

Study to Determine Safety, Pharmacokinetics, Pharmacodynamics of BAY73-4506 in Combination With mFOLFOX6 or FOLFIRI

Completed· Bayer logo

Bayer·Phase 1·NCT00934882·45 enrolled

Show 3 more trials

Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination

Completed· Bayer logo

Bayer·Phase 1·NCT01973868·42 enrolled

The Effect of Food (High Fat and Low Fat Breakfast) on the Pharmacokinetics of Regorafenib

Completed· Bayer logo

Bayer·Phase 1·NCT01002378·24 enrolled

Effect of Neomycin on the Pharmacokinetics of Regorafenib

Completed· Bayer logo

Bayer·Phase 1·NCT02001909·27 enrolled

Pembrolizumab3 trials

Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC

Completed· Bayer logo

Bayer·Phase 1·NCT03347292·58 enrolled

Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7

Terminated·TTranslational Research in Oncology·Phase 3·NCT04777851·45 enrolled

TATE and Pembrolizumab (MK3475) in mCRC and NSCLC

Recruiting·TTeclison Ltd.·Phase 2·NCT04701476·110 enrolled

Chemotherapy3 trials

Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy

Active, not recruiting·NNational Cancer Center Hospital East·Phase 1/2·NCT05394740·30 enrolled

RegoNivo vs Standard of Care Chemotherapy in AGOC

Active, not recruiting·AAustralasian Gastro-Intestinal Trials Group·Phase 3·NCT04879368·450 enrolled

A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer

Terminated·NNSABP Foundation Inc·Phase 3·NCT02664077·34 enrolled

Pancreatic Cancer3 trials

A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Treatment of Advanced Pancreatic Cancer

Recruiting·—·Phase 1/2·NCT07040228·23 enrolled

A Study of Regorafenib in Advanced Pancreatic Cancer Patients

Completed·WWake Forest University Health Sciences·Phase 2·NCT02080260·20 enrolled

Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer

Terminated·—·Phase 2·NCT02383433·2 enrolled

Glioblastoma3 trials

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Recruiting·NNeonc Technologies, Inc.·Phase 1/2·NCT06047379·134 enrolled

Regorafenib in Patients With Relapsed Glioblastoma. IOV-GB-1-2020 REGOMA-OSS

Completed·IIstituto Oncologico Veneto IRCCS··NCT04810182·192 enrolled

Regorafenib in Relapsed Glioblastoma

Completed·IIstituto Oncologico Veneto IRCCS·Phase 2·NCT02926222·119 enrolled

Non-Small Cell Lung Cancer2 trials

Determination of Safety, Efficacy, and Pharmacokinetics of "Regorafenib" Combined With Pemetrexed and Cisplatin in Patients With Nonsquamous Non-Small Cell Lung Cancer

Terminated· Bayer logo

Bayer·Phase 1·NCT01187615·9 enrolled

Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer

Completed·SStanford University·Phase 2·NCT03520842·22 enrolled

Cholangiocarcinoma2 trials

Regorafenib Versus Placebo to Treat Cholangiocarcinoma

Unknown status·EErasme University Hospital·Phase 2·NCT02162914·66 enrolled

A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy

Completed·NNathan Bahary, MD·Phase 2·NCT02053376·43 enrolled

Gastric Cancer2 trials

Study Maintenance Regorafenib vs Placebo, no Progression Patients After I Line Chemotherapy Metastatic Gastric Cancer

Completed·GGruppo Oncologico Italiano di Ricerca Clinica·Phase 2·NCT03627728·67 enrolled

FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT01913639·39 enrolled

Biliary Tract Cancer2 trials

Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer

Completed·IInstitut du Cancer de Montpellier - Val d'Aurelle·Phase 1/2·NCT02386397·66 enrolled

The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers

Active, not recruiting·UUniversity of Kansas Medical Center·Phase 1/2·NCT04781192·40 enrolled

Phase II2 trials

Phase II Study of Perindopril and Regorafenib in mCRC

Completed·BBritish Columbia Cancer Agency·Phase 2·NCT02651415·12 enrolled

Phase II Study of Regorafenib Continuous Dosing of Regorafenib in Patients With GISTs

Completed·—·Phase 2·NCT02889328·25 enrolled

Refractory Solid Tumors2 trials

A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors

Completed·CCStone Pharmaceuticals·Phase 1/2·NCT04200404·19 enrolled

Phase I Study of BAY73-4506 in Chinese Patients With Advanced, Refractory Solid Tumors

Completed· Bayer logo

Bayer·Phase 1·NCT01096030·33 enrolled

Sarcoma2 trials

SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes

Completed·SSarcoma Alliance for Research through Collaboration·Phase 2·NCT02048371·131 enrolled

Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation

Active, not recruiting· Amgen logo

Amgen·Phase 3·NCT05198934·160 enrolled

Liver Cancer2 trials

Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer

Active, not recruiting·—·Phase 2·NCT05194293·4 enrolled

Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors

Completed· Bayer logo

Bayer·Phase 2·NCT04696055·95 enrolled

Melanoma2 trials

Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma

Terminated·UUniversity of California, San Francisco·Phase 2·NCT02587650·1 enrolled

A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma

Unknown status·UUniversitair Ziekenhuis Brussel·Phase 2·NCT05370807·48 enrolled

Unresectable2 trials

A Phase II Uncontrolled Study of BAY73-4506 in Previously Untreated Patients With Metastatic or Unresectable RCC

Completed· Bayer logo

Bayer·Phase 2·NCT00664326·49 enrolled

Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST

Completed·—·Phase 1·NCT02164240·14 enrolled

HCC2 trials

Optimization for Regorafenib in HCC

Terminated·SSC Liver Research Consortium, LLC·Phase 2·NCT04476329·7 enrolled

A Real World Study of Regogfinib in HCC

Unknown status·ZZhongda Hospital··NCT05557656·800 enrolled

Intrahepatic Cholangiocarcinoma1 trial

Second Line Therapy for Advanced Intrahepatic Cholangiocarcinoma

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT05535647·60 enrolled

First-line1 trial

Second-line FOLFOX With or Without Regorafenib in mCRC Patients Failed to First-line Irinotecan Plus Fluoropyrimidines

Withdrawn·—·Phase 3·NCT01786538

Macular Degeneration1 trial

Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration

Terminated· Bayer logo

Bayer·Phase 2·NCT02222207·52 enrolled

Electroacupuncture1 trial

Regorafenib and Sintilimab in Combination with Electroacupuncture in MSS CRC

Recruiting·TThe First People's Hospital of Changzhou·N/A·NCT06456515·30 enrolled

Toripalimab1 trial

Phase II Study of Regorafenib and Toripalimab Combined With RFA in Patients With CRCLM

Unknown status·SSun Yat-sen University·Phase 2·NCT05485909·32 enrolled

Immune Checkpoint Inhibitor1 trial

GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC.

Recruiting·—·Phase 2·NCT06558773·120 enrolled

Safety and Efficacy1 trial

The Safety and Efficacy of HAIC+Tislelizumab+Regorafenib in Patients With Colorectal Liver Metastases

Unknown status·PPeking University Cancer Hospital & Institute·Phase 2·NCT05877001·20 enrolled

Rhabdomyosarcoma1 trial

FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

Recruiting·UUniversity of Birmingham·Phase 1/2·NCT04625907·1,672 enrolled

mCRC1 trial

Zinc Supplement in Regorafenib Treated mCRC Patient

Completed·—·Phase 2·NCT03898102·65 enrolled

Advanced Stage Cancer1 trial

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Recruiting·AAmerican Society of Clinical Oncology·Phase 2·NCT02693535·4,200 enrolled

Nivolumab1 trial

An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT03377361·325 enrolled

Intestinal Cancer1 trial

A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer

Completed· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 1/2·NCT02024607·495 enrolled

Esophageal Cancer1 trial

A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer

Unknown status·AAustralasian Gastro-Intestinal Trials Group·Phase 3·NCT02773524·250 enrolled

Ovarian Carcinoma1 trial

REGorafenib vsTamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological Progression

Completed·AARCAGY/ GINECO GROUP·Phase 2·NCT02584465·68 enrolled

Gastric Carcinoma1 trial

Regorafenib in Combination With Paclitaxel in Advanced Oesophagogastric Carcinoma

Completed·—·Phase 1/2·NCT02406170·47 enrolled

Fluorouracil1 trial

Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRC

Terminated·FFox Chase Cancer Center·Phase 2·NCT03099486·2 enrolled

Acute Myeloid Leukemia1 trial

Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia

Suspended·—·Phase 1·NCT06454409·20 enrolled

Locally Advanced or Metastatic Solid Tumors1 trial

Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.

Not yet recruiting·SShanghai Runshi Pharmaceutical Technology Co., Ltd·Phase 1/2·NCT06682611·380 enrolled

Acute Lymphoblastic Leukemia1 trial

Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib

Terminated·WWake Forest University Health Sciences·Phase 2·NCT04327700·2 enrolled

Locally-advanced Rectal Cancer1 trial

Neoadjuvant Treatment With Regorafenib and Capecitabine Combined With Radiotherapy in Locally Advanced Rectal Cancer

Terminated·SSwiss Cancer Institute·Phase 1·NCT02910843·25 enrolled

Urothelial Cancer1 trial

Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477)

Completed·UUniversity of Alabama at Birmingham·Phase 2·NCT02459119·17 enrolled

Genomic Alterations1 trial

Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT02795156·100 enrolled

Advanced Solid Cancers1 trial

An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT03994601·219 enrolled

Rectal Cancer1 trial

Neoadjuvant Regorafenib in Combination with Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer

Recruiting·JJules Bordet Institute·Phase 2·NCT04503694·72 enrolled

Patients With Solid Tumors1 trial

Phase I Study to Investigate Pharmacokinetics and Safety of BAY73-4506 in Asian (Japanese) Patients With Solid Tumors.

Completed· Bayer logo

Bayer·Phase 1·NCT00960258·15 enrolled

Recurrent or Refractory1 trial

A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy

Completed· Bayer logo

Bayer·Phase 1·NCT02085148·62 enrolled

Ewing sarcoma1 trial

Phase Ib / Regorafenib With Conventional Chemotherapy/Newly Diagnosed Patients/ Multimetastatic Ewing Sarcoma

Active, not recruiting·GGustave Roussy, Cancer Campus, Grand Paris·Phase 1·NCT05830084·23 enrolled

Metastatic Cancer1 trial

Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer

Terminated· Bayer logo

Bayer·Phase 1·NCT02168777·20 enrolled

Cardiovascular1 trial

Open Label Regorafenib Study to Evaluate Cardiovascular Safety Parameters, Tolerability, and Anti-tumor Activity

Completed· Bayer logo

Bayer·Phase 1·NCT01339104·53 enrolled

Renal Impairment1 trial

Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment

Completed· Bayer logo

Bayer·Phase 1·NCT01853046·24 enrolled

Colorectal Adenocarcinoma1 trial

Efficacy and the Safety of Regorafenib in Patients Aged More Than 70 Years With a Metastatic Colorectal Adenocarcinoma .

Completed·FFederation Francophone de Cancerologie Digestive·Phase 2·NCT02788006·43 enrolled

Malignant Tumors1 trial

Effect of Regorafenib on Digoxin and Rosuvastatin in Patients With Advanced Solid Malignant Tumors.

Completed· Bayer logo

Bayer·Phase 1·NCT02106845·42 enrolled

Osteosarcoma1 trial

SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma

Active, not recruiting·SSarcoma Alliance for Research through Collaboration·Phase 2·NCT04803877·48 enrolled

Meningioma1 trial

Regorafenib for Recurrent Grade 2 and 3 Meningioma (MIRAGE Trial)

Recruiting·IIstituto Oncologico Veneto IRCCS·Phase 2·NCT06275919·104 enrolled

COVID-191 trial

An Observational Study, Called ROCURS, to Learn About COVID-19 Related Outcomes in People With Cancer Who Are Treated With Tyrosine Kinase Inhibitors (TKIs) Including Regorafenib or Sorafenib

Completed· Bayer logo

Bayer··NCT05594147·4,103 enrolled

Solid Tumors1 trial

A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors

Completed· Bayer logo

Bayer·Phase 2·NCT04704154·175 enrolled

AIN1 trial

Regorafenib Phase I Study in Mainland Chinese Patients

Completed· Bayer logo

Bayer·Phase 1·NCT02398513·18 enrolled

Recruiting·FFudan University·Phase 2·NCT05970705·101 enrolled

Efficacy1 trial

Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06087263·3 enrolled

Advanced Malignancy1 trial

Regorafenib and Cetuximab in Patients With Advanced Malignancy

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT02095054·39 enrolled

Advanced Solid Tumors1 trial

A Study of CS1003 in Subjects With Advanced Solid Tumors

Completed·CCStone Pharmaceuticals·Phase 1·NCT03475251·108 enrolled

Bone Sarcoma1 trial

A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas

Active, not recruiting·UUNICANCER·Phase 2·NCT02389244·163 enrolled

Thyroid Cancer1 trial

A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer

Active, not recruiting·—·Phase 2·NCT02657551·8 enrolled

Advanced Stage1 trial

Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC

Recruiting·HHumanity & Health Medical Group Limited·Phase 2·NCT03899428·30 enrolled

Ovarian Cancer1 trial

Use of Regorafenib in Recurrent Epithelial Ovarian Cancer

Completed·NNational Cancer Centre, Singapore·Phase 2·NCT02736305·21 enrolled

Unspecified6 trials

The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib

Completed·EErasmus Medical Center·Phase 4·NCT02800330·31 enrolled

Regorafenib Post-marketing Surveillance in Japan

Completed· Bayer logo

Bayer··NCT01933958·72 enrolled

Stivarga Real Life Evidence in Hungary

Completed· Bayer logo

Bayer··NCT02656524·400 enrolled

Show 3 more trials

Stivarga Regulatory Post-Marketing Surveillance Study in Korea

Completed· Bayer logo

Bayer··NCT02106858·316 enrolled

BAY73-4506 Probe Substrate Study

Completed· Bayer logo

Bayer·Phase 1·NCT01287598·41 enrolled

Regorafenib Post-marketing Surveillance

Completed· Bayer logo

Bayer··NCT01843400·1,301 enrolled

Regulatory

FDA Approval Timeline[5]

Sep 27, 2012

STIVARGA

NDA NDA203085

Sources

References

[1]
ClinicalTrials.gov — 268 trial records for Regorafenib. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Stivarga drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Regorafenib compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Regorafenib. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA203085). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Stivarga. U.S. Food & Drug Administration.
[7]
PubMed — 1 publication indexed for Regorafenib. U.S. National Library of Medicine.
[8]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Multi-Kinase Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Bayer

Patent Landscape[6]

Patent Cliff

Jun 2, 2030

Earliest patent expiration — generic entry possible after this date

Patent #Expires

8680124Jun 2, 2030

8637553Feb 16, 2031

9458107Apr 8, 2031

9957232Jul 9, 2032

Key Publications[7]

Regorafenib in Refractory Metastatic Colorectal Cancer: CORRECT

Lancet OncolMar 10, 2022DOI: 10.1016/S1470-2045(22)00050-6

Stivarga

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Trials by Indication[1]

Metastatic Colorectal Cancer47 trials

Colorectal Cancer29 trials

Hepatocellular Carcinoma17 trials

Gastrointestinal Stromal Tumor7 trials

Treatment7 trials

Tics6 trials

Pembrolizumab3 trials

Chemotherapy3 trials

Pancreatic Cancer3 trials

Glioblastoma3 trials

Non-Small Cell Lung Cancer2 trials

Cholangiocarcinoma2 trials

Gastric Cancer2 trials

Biliary Tract Cancer2 trials

Phase II2 trials

Refractory Solid Tumors2 trials

Sarcoma2 trials

Liver Cancer2 trials

Melanoma2 trials

Unresectable2 trials

HCC2 trials

Intrahepatic Cholangiocarcinoma1 trial

First-line1 trial

Macular Degeneration1 trial

Electroacupuncture1 trial

Toripalimab1 trial

Immune Checkpoint Inhibitor1 trial

Safety and Efficacy1 trial

Rhabdomyosarcoma1 trial

mCRC1 trial

Advanced Stage Cancer1 trial

Nivolumab1 trial

Intestinal Cancer1 trial

Esophageal Cancer1 trial

Ovarian Carcinoma1 trial

Gastric Carcinoma1 trial

Fluorouracil1 trial

Acute Myeloid Leukemia1 trial

Locally Advanced or Metastatic Solid Tumors1 trial

Acute Lymphoblastic Leukemia1 trial

Locally-advanced Rectal Cancer1 trial

Urothelial Cancer1 trial

Genomic Alterations1 trial

Advanced Solid Cancers1 trial

Rectal Cancer1 trial

Patients With Solid Tumors1 trial

Recurrent or Refractory1 trial

Ewing sarcoma1 trial

Metastatic Cancer1 trial

Cardiovascular1 trial

Renal Impairment1 trial

Colorectal Adenocarcinoma1 trial

Malignant Tumors1 trial

Osteosarcoma1 trial

Meningioma1 trial

COVID-191 trial

Solid Tumors1 trial

AIN1 trial

PD-1antibody1 trial

Metastasis1 trial

Monotherapy1 trial

Efficacy1 trial

Advanced Malignancy1 trial

Advanced Solid Tumors1 trial

Bone Sarcoma1 trial

Thyroid Cancer1 trial

Advanced Stage1 trial

Ovarian Cancer1 trial

Unspecified6 trials

FDA Approval Timeline[5]

References

Drug Info

Quick Facts